{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:01:48Z","timestamp":1790002908565,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08548-2","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:46:09Z","timestamp":1787737569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of amisulpride augmentation versus other antipsychotics in clozapine-treated adolescents: a real-world retrospective study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-6288","authenticated-orcid":false,"given":"Binay Kayan","family":"Ocakoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0734-5602","authenticated-orcid":false,"given":"Ay\u015feg\u00fcl","family":"Tonyal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0897-114X","authenticated-orcid":false,"given":"U\u011fur","family":"Karaba\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7515-6939","authenticated-orcid":false,"given":"Zeynep G\u00fcltekin","family":"Ta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-2429","authenticated-orcid":false,"given":"Damla Kasap","family":"\u00dcst\u00fcnda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9109-6559","authenticated-orcid":false,"given":"G\u00fcl","family":"Kara\u00e7etin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"5","key":"8548_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1089\/cap.2015.0097","volume":"26","author":"M Stentebjerg-Olesen","year":"2016","unstructured":"Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU, Jeppesen P. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol. 2016;26(5):410\u201327. https:\/\/doi.org\/10.1089\/cap.2015.0097.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"8548_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","volume":"36","author":"C Correll","year":"2022","unstructured":"Correll C, Agid O, Crespo-Facorro B, De Bartolomeis A, Fagiolini A, Sepp\u00e4l\u00e4 N, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022;36(7):659\u201379. https:\/\/doi.org\/10.1007\/s40263-022-00932-2.","journal-title":"CNS Drugs"},{"issue":"4","key":"8548_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biomedicines11041072","volume":"11","author":"V Peitl","year":"2023","unstructured":"Peitl V, Pulji\u0107 A, \u0160krobo M, Nadalin S, Dunki\u0107 F, Karlovi\u0107 D. Clozapine in treatment-resistant schizophrenia and its augmentation with electroconvulsive therapy in ultra-treatment-resistant schizophrenia. Biomedicines. 2023;11(4):11. https:\/\/doi.org\/10.3390\/biomedicines11041072.","journal-title":"Biomedicines"},{"key":"8548_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fpsyt.2022.1069432","volume":"13","author":"O Vasiliu","year":"2022","unstructured":"Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: what is the evidence? Front Psychiatry. 2022;13:13. https:\/\/doi.org\/10.3389\/fpsyt.2022.1069432.","journal-title":"Front Psychiatry"},{"issue":"1","key":"8548_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1055\/s-2007-993209","volume":"41","author":"H Assion","year":"2008","unstructured":"Assion H, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41(1):24\u201328. https:\/\/doi.org\/10.1055\/s-2007-993209.","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"8548_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/2045125318762365","volume":"8","author":"T Barnes","year":"2018","unstructured":"Barnes T, Leeson V, Paton C, Marston L, Osborn D, Kumar R, et al. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol. 2018;8(7):185\u201397. https:\/\/doi.org\/10.1177\/2045125318762365.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"49","key":"8548_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21490","volume":"21","author":"T Barnes","year":"2017","unstructured":"Barnes T, Leeson V, Paton C, Marston L, Davies L, Whittaker W, et al. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2017;21(49):1\u201356. https:\/\/doi.org\/10.3310\/hta21490.","journal-title":"Health Technol Assess"},{"key":"8548_CR8","doi-asserted-by":"publisher","unstructured":"Wagner E, Kane J, Correll C, Howes O, Siskind D, Honer W, et al. Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an International expert survey among the treatment response and resistance in psychosis (TRRIP) working group. Schizophr Bull. 2020. https:\/\/doi.org\/10.1093\/schbul\/sbaa060.","DOI":"10.1093\/schbul\/sbaa060"},{"key":"8548_CR9","doi-asserted-by":"publisher","first-page":"103375","DOI":"10.1016\/j.ajp.2022.103375","volume":"79","author":"T-C Yeh","year":"2022","unstructured":"Yeh T-C, Correll C, Yang F-C, Chen M-H, Tseng P, Hsu C-W, et al. Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment. Asian J Psychiatr. 2022;79:103375. https:\/\/doi.org\/10.1016\/j.ajp.2022.103375.","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"8548_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1176\/ajp.155.4.505","volume":"155","author":"C Trichard","year":"1998","unstructured":"Trichard C, Paill\u00e8re-Martinot M, Attar-L\u00e9vy D, Recassens C, Monnet F, Martinot J. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Phychol. 1998;155(4):505\u201308. https:\/\/doi.org\/10.1176\/ajp.155.4.505.","journal-title":"Am J Phychol"},{"key":"8548_CR11","doi-asserted-by":"publisher","unstructured":"Zhu M, Liu Z, Hu Q, Yang J, Jin Y, Zhu N, et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res. 2022;9(1). https:\/\/doi.org\/10.1186\/s40779-022-00420-0.","DOI":"10.1186\/s40779-022-00420-0"},{"issue":"7","key":"8548_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","volume":"268","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625\u201339. https:\/\/doi.org\/10.1007\/s00406-018-0869-3.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"8548_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","volume":"88","author":"B Murphy","year":"2006","unstructured":"Murphy B, Chung Y-C, Park T, McGorry P. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006;88:5\u201325. https:\/\/doi.org\/10.1016\/j.schres.2006.07.002.","journal-title":"Schizophr Res"},{"issue":"1","key":"8548_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1055\/s-2007-993209","volume":"41","author":"H Assion","year":"2008","unstructured":"Assion H, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41(1):24\u201328. https:\/\/doi.org\/10.1055\/s-2007-993209.","journal-title":"Pharmacopsychiatry"},{"key":"8548_CR15","doi-asserted-by":"publisher","unstructured":"Bahk W, Woo Y, Park S, Yoon B, Wang S, Kim M. Amisulpride augmentation in schizophrenia patients with poor response to olanzapine: a 4-week, randomized, Rater-Blind, controlled, pilot study. Eur Psychiatry. 2023;66. https:\/\/doi.org\/10.1192\/j.eurpsy.2023.2322.","DOI":"10.1192\/j.eurpsy.2023.2322"},{"key":"8548_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/bf02849987","volume":"24","author":"Y Gen\u00e7","year":"2007","unstructured":"Gen\u00e7 Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007;24:1\u201313. https:\/\/doi.org\/10.1007\/bf02849987.","journal-title":"Adv Ther"},{"issue":"8","key":"8548_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/0004867418772351","volume":"52","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52(8):751\u201367. https:\/\/doi.org\/10.1177\/0004867418772351.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"8548_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1017\/neu.2022.30","volume":"35","author":"S Grover","year":"2023","unstructured":"Grover S, Sarkar S, Sahoo S. Augmentation strategies for clozapine resistance: a systematic review and meta-analysis. Acta Neuropsychiatrica. 2023;35(2):65\u201375. https:\/\/doi.org\/10.1017\/neu.2022.30.","journal-title":"Acta Neuropsychiatrica"},{"key":"8548_CR19","unstructured":"Turkish Medicines and Medical Devices Agency (TITCK). Leponex (clozapine) summary of product characteristics (K\u0131sa \u00dcr\u00fcn Bilgisi). Ankara, T\u00fcrkiye: ministry of health. n.d. https:\/\/www.titck.gov.tr. July 7, 2026, from."},{"key":"8548_CR20","doi-asserted-by":"crossref","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42(suppl_1):S90\u201394.","DOI":"10.1093\/schbul\/sbv167"},{"issue":"2","key":"8548_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"S Kay","year":"1987","unstructured":"Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"S7","key":"8548_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1192\/s0007125000291514","volume":"155","author":"S Kay","year":"1989","unstructured":"Kay S, Opler L, Lindenmayer J. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry. 1989;155(S7):59\u201365. https:\/\/doi.org\/10.1192\/s0007125000291514.","journal-title":"Br J Psychiatry"},{"issue":"44","key":"8548_CR23","first-page":"23","volume":"14","author":"AE Kostako\u011flu","year":"1999","unstructured":"Kostako\u011flu AE, Batur S, Tiryaki A, G\u00f6\u011f\u00fc\u015f A. Pozitif ve negatif sendrom \u00f6l\u00e7e\u011finin (PANSS) T\u00fcrk\u00e7e uyarlamas\u0131n\u0131n ge\u00e7erlilik ve g\u00fcvenilirli\u011fi. T\u00fcrk Psikoloji Dergisi. 1999;14(44):23\u201332.","journal-title":"T\u00fcrk Psikoloji Dergisi"},{"issue":"5_suppl","key":"8548_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0269881112442016","volume":"26","author":"J Cookson","year":"2012","unstructured":"Cookson J, Hodgson R, Wildgust H. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012;26(5_suppl):42\u201351. https:\/\/doi.org\/10.1177\/0269881112442016.","journal-title":"J Psychopharmacol"},{"issue":"20","key":"8548_CR25","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"P Haddad","year":"2004","unstructured":"Haddad P, Wieck A. Antipsychotic-induced Hyperprolactinaemia. Drugs. 2004;64(20):2291\u2013314. https:\/\/doi.org\/10.2165\/00003495-200464200-00003.","journal-title":"Drugs"},{"issue":"5","key":"8548_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421\u201353. https:\/\/doi.org\/10.1007\/s40263-014-0157-3.","journal-title":"CNS Drugs"},{"key":"8548_CR27","doi-asserted-by":"publisher","unstructured":"Hoekstra S, Bartz-Johannessen C, Sinkeviciute I, Reitan S, Kroken R, L\u00f8berg E, et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophr. 2021;7. https:\/\/doi.org\/10.1038\/s41537-021-00170-3.","DOI":"10.1038\/s41537-021-00170-3"},{"key":"8548_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fpsyt.2023.1014540","volume":"14","author":"J Pattnaik","year":"2023","unstructured":"Pattnaik J, Panda U, Chandran S, Padhy S, Ravan J. Treatment resistant psychosis in children and adolescents and clozapine: nuances. Front Psychiatry. 2023;14:14. https:\/\/doi.org\/10.3389\/fpsyt.2023.1014540.","journal-title":"Front Psychiatry"},{"issue":"6","key":"8548_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1192\/bjp.2024.140","volume":"225","author":"L Balbuena","year":"2024","unstructured":"Balbuena L, Halayka S, Lee A, Ahmed AG, Hinz T, Kolla N, et al. Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada. Br J Psychiatry. 2024;225(6):572\u201378. https:\/\/doi.org\/10.1192\/bjp.2024.140.","journal-title":"Br J Psychiatry"},{"key":"8548_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.euroneuro.2024.02.005","volume":"82","author":"C Correll","year":"2024","unstructured":"Correll C, Arango C, Fagerlund B, Galderisi S, Kas M, Leucht S. Identification and treatment of individuals with childhood-onset and early-onset schizophrenia. Eur Neuropsychopharmacol. 2024;82:57\u201371. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.02.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"8548_CR31","doi-asserted-by":"crossref","unstructured":"Liang Y, Yu X. Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study. Neuropsychiatric disease and treatment. 2017;1703\u201312.","DOI":"10.2147\/NDT.S140905"},{"issue":"1","key":"8548_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1192\/bjp.166.1.68","volume":"166","author":"P Boyer","year":"1995","unstructured":"Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1995;166(1):68\u201372.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"8548_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1192\/bjp.170.1.18","volume":"170","author":"H Loo","year":"1997","unstructured":"Loo H, Poirier-Littre M-F, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170(1):18\u201322. https:\/\/doi.org\/10.1192\/bjp.170.1.18.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"8548_CR34","first-page":"130","volume":"152","author":"M-L Paill\u00e8re-Martinot","year":"1995","unstructured":"Paill\u00e8re-Martinot M-L, Lecrubier Y, Martinot J-L, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Phychol. 1995;152(1):130\u201334.","journal-title":"Am J Phychol"},{"issue":"1","key":"8548_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/cap.2021.0092","volume":"32","author":"M Adnan","year":"2022","unstructured":"Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S. Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2022;32(1):2\u201311. https:\/\/doi.org\/10.1089\/cap.2021.0092.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"8548_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2017","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2017;28(6):659\u201374. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008.","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"issue":"4","key":"8548_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/02698811251414347","volume":"40","author":"M Uysal","year":"2026","unstructured":"Uysal M, Ayva DA, Ceylan M, Hesap\u00e7\u0131o\u011flu ST. Clozapine treatment in adolescents with schizophrenia and autism spectrum disorder: comparative clinical profiles and treatment outcomes from a retrospective study. J Psychopharmacol. 2026;40(4):554\u201362. https:\/\/doi.org\/10.1177\/02698811251414347.","journal-title":"J Psychopharmacol"},{"key":"8548_CR38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1089\/cap.2015.0020","volume":"26","author":"O Yalcin","year":"2016","unstructured":"Yalcin O, Kaymak G, Erdogan A, Tan\u0131d\u0131r C, Karacetin G, Kilicoglu AG, et al. A retrospective investigation of clozapine treatment in autistic and nonautistic children and adolescents in an inpatient clinic in Turkey. J Child Adolesc Psychopharmacol. 2016;26:815\u201321. https:\/\/doi.org\/10.1089\/cap.2015.0020.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"8548_CR39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1089\/cap.2018.0036","volume":"28","author":"L Steinauer","year":"2018","unstructured":"Steinauer L, Leung J, Burkey BW, McGrane I, Letts V, Goren J, et al. A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization. J Child Adolesc Psychopharmacol. 2018;28(9):615\u201319. https:\/\/doi.org\/10.1089\/cap.2018.0036.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"8548_CR40","doi-asserted-by":"publisher","unstructured":"Wagner E, Siafis S, Fernando P, Falkai P, Honer W, R\u00f6h A, et al. Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. Transl Psychiatry. 2021;11. https:\/\/doi.org\/10.1038\/s41398-021-01613-2.","DOI":"10.1038\/s41398-021-01613-2"},{"key":"8548_CR41","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","volume":"28","author":"S Siafis","year":"2023","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023;28:3267\u201377. https:\/\/doi.org\/10.1038\/s41380-023-02203-y.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"8548_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/jcp.0b013e3182214aad","volume":"31","author":"H Uchida","year":"2011","unstructured":"Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo D. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(4):497\u2013502. https:\/\/doi.org\/10.1097\/jcp.0b013e3182214aad.","journal-title":"J Clin Psychopharmacol"},{"key":"8548_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.schres.2024.09.030","volume":"274","author":"F De Beer","year":"2024","unstructured":"De Beer F, Wijnen B, Wouda L, Koops S, Gangadin S, Veling W, et al. Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients. Schizophr Res. 2024;274:299\u2013306. https:\/\/doi.org\/10.1016\/j.schres.2024.09.030.","journal-title":"Schizophr Res"},{"key":"8548_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40272-025-00730-5","volume":"28","author":"F Besag","year":"2026","unstructured":"Besag F, Vasey M, Hollis C, Taylor D. Neurological adverse effects of antipsychotic medication in children and young people. Paediatr Drugs. 2026;28:127\u201357. https:\/\/doi.org\/10.1007\/s40272-025-00730-5.","journal-title":"Paediatr Drugs"},{"issue":"8","key":"8548_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4088\/JCP.0808e24","volume":"69","author":"C Correll","year":"2008","unstructured":"Correll C. Paediatr Drugs. J Clin Psychiatry. 2008;69(8):26\u201336. https:\/\/doi.org\/10.4088\/JCP.0808e24.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"8548_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/070674379804300608","volume":"43","author":"R Lewis","year":"1998","unstructured":"Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry. 1998;43(6):596\u2013604. https:\/\/doi.org\/10.1177\/070674379804300608.","journal-title":"Can J Psychiatry"},{"key":"8548_CR47","first-page":"20","volume":"65 Suppl 6","author":"B Mcconville","year":"2004","unstructured":"Mcconville B, Sorter M. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004;65 Suppl 6:20\u201329. https:\/\/consensus.app\/papers\/treatment-challenges-and-safety-considerations-for-mcconville-sorter\/38e0408f51475364bd7f8500b5ef70c5\/.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"8548_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/jcp.0b013e3182549259","volume":"32","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian Meta-analysis. J Clin Psychopharmacol. 2012;32(3):309. https:\/\/doi.org\/10.1097\/jcp.0b013e3182549259.","journal-title":"J Clin Psychopharmacol"},{"key":"8548_CR49","doi-asserted-by":"publisher","unstructured":"Galva\u00f1 J, Distefano G, Echeverria I, Aymerich C, Abreg\u00fa-Crespo R, Lorente MMA, et al. Risk of extrapyramidal symptoms associated with antipsychotic drugs in children and adolescents: a systematic review and meta-analysis of double-blind randomised placebo-controlled trials. Res Square. 2026. https:\/\/doi.org\/10.21203\/rs.3.rs-9601341\/v1.","DOI":"10.21203\/rs.3.rs-9601341\/v1"},{"issue":"3","key":"8548_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","volume":"56","author":"A Pagsberg","year":"2017","unstructured":"Pagsberg A, Tarp S, Glintborg D, Stenstr\u00f8m AD, Fink-Jensen A, Correll C, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Psy. 2017;56(3):191\u2013202. https:\/\/doi.org\/10.1016\/j.jaac.2016.12.013.","journal-title":"J Am Acad Child Psy"},{"issue":"1","key":"8548_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/schbul\/sbm109","volume":"34","author":"S Kumra","year":"2008","unstructured":"Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34(1):60\u201371. https:\/\/doi.org\/10.1093\/schbul\/sbm109.","journal-title":"Schizophr Bull"},{"issue":"4","key":"8548_CR52","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.cpem.2012.09.005","volume":"13","author":"J Rasimas","year":"2012","unstructured":"Rasimas J, Liebelt E. Adverse effects and toxicity of the atypical antipsychotics: what is important for the pediatric emergency medicine practitioner? Clin Pediatr Emerg Med. 2012;13(4):300\u201310. https:\/\/doi.org\/10.1016\/j.cpem.2012.09.005.","journal-title":"Clin Pediatr Emerg Med"},{"issue":"3","key":"8548_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/jcp.0b013e3182549259","volume":"32","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian Meta-analysis. J Clin Psychopharmacol. 2012;32(3):309. https:\/\/doi.org\/10.1097\/jcp.0b013e3182549259.","journal-title":"J Clin Psychopharmacol"},{"key":"8548_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.npp.1300327","volume":"29","author":"L Sikich","year":"2003","unstructured":"Sikich L, Hamer R, Bashford R, Sheitman B, Lieberman J. A pilot study of risperidone, Olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2003;29:133\u201345. https:\/\/doi.org\/10.1038\/sj.npp.1300327.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"8548_CR55","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli E, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214\u201332. https:\/\/doi.org\/10.1002\/wps.20765.","journal-title":"World Psychiatry"},{"key":"8548_CR56","doi-asserted-by":"publisher","unstructured":"Bucato\u015f B, Romo\u015fan A, Dehelean L, Romosan R, Cojocaru A, Kundnani N, et al. Pharmacogenetic variability and quality of life in adolescent patients with schizophrenia: the impact of metabolizer status, symptom severity, and adverse reactions to antipsychotic treatment. J Clin Med. 2026;15. https:\/\/doi.org\/10.3390\/jcm15082912.","DOI":"10.3390\/jcm15082912"},{"issue":"1","key":"8548_CR57","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bandc.2009.10.013","volume":"72","author":"D Wahlstrom","year":"2010","unstructured":"Wahlstrom D, Collins P, White T, Luciana M. Developmental changes in dopamine neurotransmission in adolescence: behavioral implications and issues in assessment. Brain Cognition. 2010;72(1):146\u201359. https:\/\/doi.org\/10.1016\/j.bandc.2009.10.013.","journal-title":"Brain Cognition"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08548-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:12:11Z","timestamp":1789999931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08548-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8548"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08548-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board (IRB) of Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Research and Training Hospital for Psychiatry, Neurology and Neurosurgery (Protocol No: 2022\/160). The study was approved by the Institutional Review Board (IRB) of Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, and the need for consent was waived because the review of the medical records is a retrospective study. Permission to access the clinical archives was obtained from the hospital management, and all information was anonymized. The study was conducted according to the ethical principles of the Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"740"}}